Your support fuels our research to #EndALS!


TDI 208

Scientists at the ALS Therapy Development Institute are testing this small molecule in an attempt to address the oxidative stress observed in the cells of PALS.


Type: Small Molecule
Stage: Preclinical
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

This potential treatment was added to our pipeline in 2015 and is currently undergoing important experiments. These tests will help us better understand its pharmacokinetics and allow us to determine a prudent dosing strategy in efficacy testing.

Comment on this Topic

(All comments are moderated before they appear here.)